Skip to main content

Table 4 Univariate Cox regression analysis influencing outcome in the ever and never treated IPF-AE groups

From: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach

Variable HR 95 % CI p-value
Age 0.968 0.919–1.020 0.221
Gender 1.927 0.600–6.186 0.270
Smoking (pack-years) 1.000 0.980–1.020 0.996
FEV1 (% predicted) 1.000 0.941–1.063 0.990
FVC (% predicted) 1.001 0.961–1.043 0.943
TLC (% predicted) 1.034 0.976–1.096 0.252
DLCO (% predicted) 1.044 0.963–1.319 0.293
Charlson comorbidity index 0.729 0.466–1.143 0.169
LTOT 1.138 0.356–3.631 0.829
Pattern of GGO in HRCT 1.650 0.737–3.696 0.223
PO2/fiO2 0.990 0.980–1.001 0.067
NIMV 2.014 0.449–9.039 0.361
Mechanical ventilation 1.966 0.646–5.992 0.234
Disease duration 1.014 0.995–1.034 0.156
Previous corticosteroid use (all exacerbation events) 3.544 1.090–11.514 0.035
Previous corticosteroid use (unique patients) 1.642 0.441–6.119 0.460
BAL performed 0.676 0.188–2.427 0.548
6MWD 0.999 0.994–1.005 0.918
  1. IPF-AE idiopathic pulmonary fibrosis acute exacerbation; FVC forced vital capacity; FEV 1 forced expiratory volume in first second; TLC total lung capacity; DLCO diffusing capacity of the lung in carbon monoxide; LTOT long-term oxygen therapy; GGO ground glass opacities; HRCT high-resolution computerized tomography; PO 2 arterial pressure of oxygen; fiO 2 fraction of inspired oxygen; NIMV non-invasive mechanical ventilation; BAL bronchoalveolar lavage; 6MWD six minute walking distance; HR hazard ratio; CI confidence of interval